Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) open the trading on November 23, 2022, with a bit cautious approach as it glided -2.31% to $73.14. During the day, the stock rose to $76.00 and sunk to $73.06 before settling in for the price of $74.87 at the close. Taking a more long-term approach, LGND posted a 52-week range of $46.83-$107.44.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 20.50%. Meanwhile, its Annual Earning per share during the time was 98.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -31.50%. This publicly-traded company’s shares outstanding now amounts to $16.89 million, simultaneously with a float of $15.93 million. The organization now has a market capitalization sitting at $1.25 billion. At the time of writing, stock’s 50-day Moving Average stood at $83.55, while the 200-day Moving Average is $93.81.
It is imperative to bring your focus towards the efficiency factor of the conglomerate that has a total of 154 employees. For the Profitability, stocks gross margin was +60.59, operating margin was +14.90 and Pretax Margin of +17.07.
Ligand Pharmaceuticals Incorporated (LGND) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Ligand Pharmaceuticals Incorporated’s current insider ownership accounts for 5.80%, in contrast to 90.80% institutional ownership. According to the most recent insider trade that took place on Nov 17, this organization’s Chief Executive Officer sold 10,000 shares at the rate of 78.32, making the entire transaction reach 783,173 in total value, affecting insider ownership by 416,731. Preceding that transaction, on Nov 09, Company’s Chief Financial Officer sold 1,696 for 75.64, making the whole transaction’s value amount to 128,283. This particular insider is now the holder of 8,857 in total.
Ligand Pharmaceuticals Incorporated (LGND) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 6/29/2022 suggests? It has posted $1.03 earnings per share (EPS) beating the forecaster’s viewpoint (set at $0.43) by $0.6. This company achieved a net margin of +20.62 while generating a return on equity of 7.47. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.58 per share during the current fiscal year.
Ligand Pharmaceuticals Incorporated’s EPS decrease for this current 12-month fiscal period is -31.50% and is forecasted to reach 2.64 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 15.00% through the next 5 years, which can be compared against the 98.90% growth it accomplished over the previous five years trading on the market.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Trading Performance Indicators
Let’s observe the current performance indicators for Ligand Pharmaceuticals Incorporated (LGND). It’s Quick Ratio in the last reported quarter now stands at 1.50. The Stock has managed to achieve an average true range (ATR) of 4.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.18. Similarly, its price to free cash flow for trailing twelve months is now 13.31.
In the same vein, LGND’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.27, a figure that is expected to reach 0.98 in the next quarter, and analysts are predicting that it will be 2.64 at the market close of one year from today.
Technical Analysis of Ligand Pharmaceuticals Incorporated (LGND)
[Ligand Pharmaceuticals Incorporated, LGND] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 24.04% While, its Average True Range was 4.60.